Page last updated: 2024-08-25

rosiglitazone and Overweight

rosiglitazone has been researched along with Overweight in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (57.14)	29.6817
2010's	3 (42.86)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berry, EA; de Jong, SA; Manning, PJ; Sutherland, WH; Walker, RJ; Williams, SM	1
Abbasi, F; Lima, NK; Reaven, GM	1
Alemany, M; Cabot, C; Fernández-López, JA; Ferrer-Lorente, R	1
Arslanian, S; Lee, S; Sutton-Tyrrell, K; Tfayli, H; Ulnach, JW	1
Ensor, J; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Koenig, KB; Lee, MH; Moulder, SL; Murray, JL; Yeung, SC	1
Morin-Papunen, LC; Rautio, K; Ruokonen, A; Tapanainen, JS	1
Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Piccinni, MN; Ragonesi, PD; Salvadeo, SA	1

Trials

5 trial(s) available for rosiglitazone and Overweight

Article	Year
The effect of rosiglitazone on oxidative stress and insulin resistance in overweight individuals. Diabetes research and clinical practice, 2008, Volume: 81, Issue:2 Topics: Adult; Double-Blind Method; Female; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Overweight; Oxidative Stress; Peroxides; Placebos; Rosiglitazone; Thiazolidinediones	2008
Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:5 Topics: Adolescent; Adrenocorticotropic Hormone; Androstenes; Body Composition; Cardiovascular Diseases; Double-Blind Method; Ethinyl Estradiol; Female; Glucose Clamp Technique; Glucose Tolerance Test; Hemodynamics; Hormones; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Menstrual Cycle; Mineralocorticoid Receptor Antagonists; Overweight; Polycystic Ovary Syndrome; Risk Factors; Rosiglitazone; Stimulation, Chemical; Thiazolidinediones	2011
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1 Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Metformin; Middle Aged; Obesity; Overweight; Postmenopause; Rosiglitazone; Thiazolidinediones; Time Factors	2013
Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Human reproduction (Oxford, England), 2006, Volume: 21, Issue:6 Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Area Under Curve; Dehydroepiandrosterone; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Overweight; Placebos; Polycystic Ovary Syndrome; Rosiglitazone; Sex Hormone-Binding Globulin; Thiazolidinediones	2006
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. Archives of medical research, 2008, Volume: 39, Issue:4 Topics: Adiponectin; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Italy; Leptin; Male; Metformin; Middle Aged; Obesity; Overweight; Resistin; Rosiglitazone; Single-Blind Method; Thiazolidinediones; Tumor Necrosis Factor-alpha	2008

Other Studies

2 other study(ies) available for rosiglitazone and Overweight

Article	Year
Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone. Metabolism: clinical and experimental, 2009, Volume: 58, Issue:3 Topics: Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Overweight; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2009
Site-specific modulation of white adipose tissue lipid metabolism by oleoyl-estrone and/or rosiglitazone in overweight rats. Naunyn-Schmiedeberg's archives of pharmacology, 2010, Volume: 381, Issue:4 Topics: Adipose Tissue, White; Animals; Anti-Obesity Agents; Body Composition; Drug Interactions; Estrone; Hypoglycemic Agents; Lipid Metabolism; Lipogenesis; Lipolysis; Lipoprotein Lipase; Male; Oleic Acids; Overweight; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Wistar; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones	2010

Article

Year

Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone.

Metabolism: clinical and experimental, 2009, Volume: 58, Issue:3

Topics: Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Overweight; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones

2009

Site-specific modulation of white adipose tissue lipid metabolism by oleoyl-estrone and/or rosiglitazone in overweight rats.

Naunyn-Schmiedeberg's archives of pharmacology, 2010, Volume: 381, Issue:4

Topics: Adipose Tissue, White; Animals; Anti-Obesity Agents; Body Composition; Drug Interactions; Estrone; Hypoglycemic Agents; Lipid Metabolism; Lipogenesis; Lipolysis; Lipoprotein Lipase; Male; Oleic Acids; Overweight; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Wistar; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones

2010